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wald, HDLc, glucose, triglycerides); and resources utilization
(specialist referrals, medical visits, drugs, tests). A logistic regres-
sion analysis was used to correct the model (IC as the dependent
variable). Costs were contrasted by a multivariate ANCOVA
analysis with marginal means estimation (Bonferroni-adjust),
using SPSS 12.0 and a statistical signiﬁcance of p < 0.05.
RESULTS: 5014 patients were evaluated; mean age was 64.6 ±
12.1; 50.3% were men; 16.1% had a history of a CVE and
27.4% had IC (CI95%:26.2–28.6%). Suffering a CVE (OR =
1.2; CI95%:1.0–1.4; p = 0.021), smoking (OR = 1.2;
CI95%:1.0–1.4; p = 0.017) and retinopathy (OR = 1.5;
CI95%:1.3–1.7; p = 0.000) were independently related with IC.
Clinical parameters and resources utilization were different in IC
vs. good control patients: glucose 181.7 ± 61.8 vs. 129.1 ± 32.0
mg/dl (p = 0.000); LDLc 122.4 ± 38.0 vs. 119.7 ± 35.48 mg/dl
(p = 0.018); mean number of oral antidiabetics was 1.3 ± 0.8 vs.
1.2 ± 0.6 (p = 0.002); and insulins 0.5 ± 0.6 vs. 0.1 ± 0.4 (p =
0.000). Total cost/patient/year adjusted with covariance was
1.953.86€ (EE = 73.7) in patients with inadequate control versus
1.747.48€ (EE = 36.2) with good control (p = 0.03). The phar-
maceutical cost represents a 74.2% overall resources utilization
costs in both good and inadequate controlled patients. CON-
CLUSIONS: Smoking, CVE and retinopathy were independently
related with inadequate glycemic control. Uncontrolled diabetic
patients have a worse lipid proﬁle and a higher glucose level
despite a higher use of oral antidiabetics and insulin, and repre-
sent a higher cost/patient/year. General practice centres should
promote speciﬁc interventions to improve glycemic control in
diabetic patients.
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OBJECTIVES: Based on the type 2 diabetes cohort of the
DETECT study (Curr Med Res and Opinion; 2005; 21/4:
619–29) simulations with the EAGLE Diabetes Model (Diab
Technology & Therapeutics; 2006; 8/2: 219–36) were con-
ducted. Development of long-term complications was compared
with respect to different treatment targets for HbA1c. Addition-
ally, the outcome for a mixed patient population typically for a
general practice was assessed. METHODS: The Economic
Assessment of Glycemic Control and Longterm Effects (EAGLE)
model simulates long-term effects of diabetes treatment and
related costs. Baseline characteristics of the simulation cohorts
corresponded to type 2 patients of the DETECT study with
HbA1c > 9%: age 63 ± 11 years, diabetes duration 9 ± 7 years,
49% male, hypertension prevalence 71%, mean HbA1c 10,1 ±
1,3%. Three cohorts with different HbA1c targets were deﬁned:
a) no change; b) 8%; and c) 6.4%. A fourth cohort was com-
posed of 25% patients with target a) 60% target; b) and 15%;
and target c). All cohorts achieve respective targets within one
year followed by a yearly increase of 0.2%. Simulations were
run with 1000 patients over 10 years. RESULTS: The relative
risk reduction comparing cohort b versus no change was 19%
(MI); 17% (stroke); 12% (PAD); 7% (prolif. retinopathy); and
4% (ESRD). A treatment target according to the German dia-
betes guideline (c versus a) resulted in reductions of 30%, 27%,
20%, 11%, and 6%, respectively. Analysing the mixed cohort
demonstrated that treatment effects were similar to the results of
cohort b. CONCLUSIONS: The simulations based on a German
diabetes population demonstrate the long-term effects of various
treatment targets for HbA1c. Although a steady re-increase of
HbA1c values was assumed a signiﬁcant reduction in micro- and
macrovascular events can be achieved. Simulations of a mixed
cohort correlate to real world patient groups and could be used
for cost estimations in practice settings.
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OBJECTIVE: to assess the economic and epidemiologic impact
of diabetes in Campania a region of approximately 5.7 million
inhabitants in the south of Italy. METHOD: we collected, from
an electronic database, all prescriptions for antidiabetic drugs
reimbursed in the ﬁrst half year of 2005 in 8 local health author-
ities (60% of the overall population) of Campania. The diabetic
cohort was deﬁned as the population of subjects receiving at least
one prescription of an antidiabetic agent, classiﬁed according to
their therapeutic role using Anatomic Therapeutic Chemical
(ATC) classiﬁcation. We identiﬁed 3 groups: who received only
insulin (A) or only oral blood glucose lowering drugs (B) or both
(C). Drugs cost and drugs consumption were quantiﬁed using
NHS prospective (expressed in Euro 2005) and Deﬁned Daily
Dose system (DDD) respectively. RESULTS: The diabetic cohort
included 200,070 subjects (5.7% of the observed population):
15.3% group A (mean age 62.7 ± 17.9 y.o., 0.78 M/F), 78.5%
group B (mean age 65.7 ± 12.2 y.o., 0.85 M/F) and 6.2% group
C (mean age 66.5 ± 11.1 y.o., 0.57 M/F). The mean
drug/cost/patient was: 524.6€ group A (36.6% insulin, 27.1%
cardiovascular drugs), €290.4 group B (11.1% oral hypo-
glycemic drugs, 47.1% cardiovascular drugs) and €649.8 group
C (25.7% insulin, 5.4% oral hypoglycemic drugs, 34.6% car-
diovascular drugs). Total cost for diabetic patients represents
17.8% of the total expenditures. CONCLUSION: Chronic-
degenerative pathologies, such as diabetes, implies a relevant
social and economic impact. Expenses that are associated to the
treatment and the prevention of complications, in particular car-
diovascular problems, are registered among the main items listed
in the health care budget. Among diabetics patients the high use
of drugs for cardiovascular problems is the cost driver.
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OBJECTIVE: This study is to investigate the impact of the
National Health Insurance (NHI) reimbursement price on the
utilization of brand name oral hypoglycemic agents (OHAs) and
its generic counterparts for ambulatory care under an institu-
tional context characterized by a health care system being lack
of separating drug prescribing and dispensing as well as a hos-
pital system with a large outpatient department, likely resulting
in the monopsony power of hospitals over the wholesale market
of pharmaceuticals. METHODS: Data is from the National
Health Insurance Database 1997–2004 with 29,253 diabetic
patient cohort data in 7 years. Patients’ severity is measured by
the types of combination pharmacological therapy. The two-part
model was used to estimate the effect of reimbursement price on
A234 Abstracts
the choice and consumption of brand name and generic OHAs
for each outpatient visit in the Deﬁned Daily Dose. RESULTS:
The regression results suggested a positive relationship between
the reimbursement price and probability of prescribing brand
name OHAs (odd ratio : 1.37, 95%CI : 1.36–1.37). The lower
reimbursement price likely results in the lower consumption of
both brand name (1.23; p < 0.01) and generic (0.93; p < 0.01)
OHAs. The price elasticity of brand name OHAs is greater than
that of generics OHAs. Large scale and private hospitals tend to
prescribe generic OHAs, and those with higher accreditation
level are inclined to prescribe brand name OHAs. CONCLU-
SION: The NHI price regulation generates the proﬁt margin
between reimbursement price and acquisition cost. Reducing the
reimbursement price may squeeze the proﬁt margin from brand
name drugs, likely resulting in decreasing the probability of pre-
scribing brand name drugs. The consumption of brand name
drugs tends to be more sensitive to price adjustment than that of
generic counterparts.
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OBJECTIVES: This study aims to investigate the relative risk
reduction (RRR) and number-needed-to-treat (NNT) estimates
related to lower limb amputation events among patients with
diabetic foot ulcer wounds using Negative Pressure Wound
Therapy (V.A.C.® Therapy) compared to a similar patient pop-
ulation receiving other wound care treatments. METHODS:
RRR and NNT estimates with NPWT in relation to an ampu-
tation event were evaluated using three distinct data sources.
Two retrospective administrative databases of diabetic ulcer
patients, including a commercial and a Medicare (CMS) popu-
lation, as well as RCT data for diabetic foot wound patients were
evaluated. RRR and NNT for lower limb amputation events
were calculated and compared between groups in each of the
three populations. RESULTS: The commercial data yielded over
3500 patients, the Medicare data included over 12,700 patients,
and the RCT included 162 patients. The RRR in amputation
occurrence with NPWT vs. the control group was 34% for the
commercial patient group and 35% for the Medicare patient
group. The RRR was found to be even greater in the RCT group
where NPWT was associated with over a 70% reduction in the
risk of an amputation event. The NNT to prevent one amputa-
tion event with NPWT therapy was 14 for the commercial
patient group, 18 for the Medicare patient group and 13 for the
RCT group. Target NNTs in the range of 12–35 have been
reported for preventing a subsequent adverse event. CONCLU-
SIONS: Using three different sources, this study is the ﬁrst to
evaluate the effectiveness of NPWT therapy by reporting calcu-
lated RRR and NNT related to lower limb amputations. The
NNT to prevent an amputation event with NPWT therapy was
consistent and low, ranging from 13 to 18. This data suggests
that NPWT therapy is an effective intervention in reducing risk
of amputation events in diabetic ulcer patients.
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OBJECTIVES: Achieving therapeutic goals in Type 2 diabetes
often becomes more difﬁcult as the disease progresses; many
patients eventually require treatment beyond oral hypoglycaemic
agents (OHA). The objective of this meta-analysis was to inves-
tigate which injectable therapies were either superior/inferior to
bedtime-administered insulin glargine, (glargine) for key clinical
outcomes. METHODS: A systematic review of all published
glargine clinical trials (prior to October 2005) was conducted.
Based on pre-deﬁned inclusion criteria, the review encompassed
all randomised controlled trials of at least eight-weeks duration
that compared combination therapies (injectable therapy and
OHA(s)), in insulin naïve patients. A random effects model was
employed to incorporate the variability in between-study condi-
tions. RESULTS: Seven trials met the speciﬁed criteria, with
glargine chosen as the reference regimen. Although biphasic
insulin aspart (BIA) and insulin lispro 75/25 were more efﬁca-
cious than glargine at reducing HbA1c (in unadjusted (adjusted)
analyses further reductions of −0.46 % (−0.41) and −0.39 % (−
0.40) respectively were observed), this increase in efﬁcacy was
also associated with relative increases in the risk of experiencing
hypoglycaemic events for both insulins and increased weight gain
for BIA. Compared to glargine, exenatide and NPH were equally
as efﬁcacious at reducing HbA1c, although patients taking exe-
natide also beneﬁted from weight reduction and a reduced risk
of experiencing a nocturnal hypoglycaemic event. With respect
to fasting blood glucose, exenatide, insulin lispro 75/25 and
NPH were less efﬁcacious than glargine. CONCLUSIONS: This
meta-analysis found a slight increase in efﬁcacy observed with
the two twice-daily insulin regimens compared to glargine;
however this result must be carefully balanced against the
observed increase in adverse events, especially for patients where
weight gain or hypoglycaemic events may be an issue. When
glargine was compared to exenatide, similar HbA1c reduction
was found but exenatide treated patients had fewer nocturnal
hypoglycaemic events and experienced weight loss.
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OBJECTIVE: To determine the time that patients with type 1
and type 2 diabetes remain on their existing therapy whilst
uncontrolled, before starting insulin or intensifying their insulin
regimen. METHODS: A retrospective cohort study was con-
ducted among subjects with type 1 and type 2 diabetes. A total
of 154 clinical practices with continuous data over a 10-year
period from 1st May 1995 until 30th April 2005 were included
in this analysis. The study identiﬁed 9979 individuals with type
1 diabetes (T1) and 62,533 individuals with type 2 diabetes (T2).
Four patient groups were analysed: T1 on premix regimens; T2
prescribed ≥2 orals; T2 on basal regimen and T2 on premix reg-
imens. The main study outcome was the median time to insulin
